SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Alimera Sciences (ALIM)

Add ALIM Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board:
Last Post: 10/16/2016 10:23:03 PM - Followers: 39 - Board type: Free - Posts Today: 0

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to
treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark,
Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom.
In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and
did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.


Fox Business News interview with the CEO accounted for the news. 

FDA approves new diabetes implant 
Apr. 21, 2016 - 3:25 - Alimera Sciences CEO Dan Myers on a new diabetes implant that treats macular degeneration.

Retinal Vein Occlusion (RVO)

ILUVIEN® Patent Notices

Please see the following table for U.S. Patents covering ILUVIEN®. The absence of a U.S. Patent number as associated with ILUVIEN does not constitute a waiver of our patent, trademark, or other intellectual property rights concerning that product.



ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg

U.S. 6,217,895

U.S. 6,375,972

U.S. 6,548,078

U.S. 8,252,307

U.S. 8,574,659

U.S. 8,871,241

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient's eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops ILUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences Inc. is based out of Alpharetta, GA and has some 132 employees.

Officers and directors

Richard S. Eiswirth Jr.   President, Chief Financial Officer
C. Daniel Myers   Chief Executive Officer, Director
Kenneth E Green Ph.D.   Senior Vice President, Chief Scientific Officer
David R Holland   Senior Vice President - Sales and Marketing
Philip Ashman   Senior Vice President, European Managing Director
David Burke   Vice President
Mark J. Brooks   Independent Director
Brian K. Halak Ph.D.   Independent Director
James R. Largent   Independent Director
Peter J. Pizzo III   Independent Director

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE via CMTX - Wed Apr 27, 8:02AM CDT


Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results
Mar 2, 2016

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ALIM News: Current Report Filing (8-k) 10/20/2016 05:06:16 PM
ALIM News: Alimera Sciences Strengthens Financial Position 10/20/2016 04:42:35 PM
ALIM News: Proxy Statement (definitive) (def 14a) 10/14/2016 09:19:36 AM
ALIM News: Statement of Changes in Beneficial Ownership (4) 10/13/2016 04:15:31 PM
ALIM News: Statement of Changes in Beneficial Ownership (4) 10/13/2016 04:15:05 PM
#438  Sticky Note Fox Business News interview with the CEO accounted mick 04/21/16 02:14:57 PM
#777   ALIM News: Proxy Statement (definitive) (def 14a) 10/14/2016 09:19:36 AM mick 10/16/16 10:23:03 PM
#776   Alimera Sciences, In (ALIM) mick 10/16/16 10:22:52 PM
#775   ALIM News: Proxy Statement - Notice of Shareholders mick 10/01/16 11:48:36 AM
#774   Alimera Sciences, In (ALIM) mick 10/01/16 11:48:30 AM
#773   GREAT TRADE/ 'Alimera Sciences (ALIM)' mick 10/01/16 10:24:31 AM
#772   I'm in for the long, I've followed this Salvatore314 09/30/16 11:44:18 PM
#771   i have no problems raising a/s /////\\\\\ $26.5 mick 09/30/16 10:37:46 PM
#770   Next week should be promising Salvatore314 09/30/16 05:10:10 PM
#769   a.h./ mick 09/30/16 04:33:53 PM
#768   Looks like a rebound is on the way Salvatore314 09/29/16 10:18:21 AM
#767 mick 09/28/16 03:37:31 AM
#766   Timber CarlCarlMcB 09/28/16 03:22:17 AM
#765   ALIM News: Statement of Changes in Beneficial Ownership mick 09/18/16 01:45:34 PM
#764   Alimera Sciences, In (ALIM) mick 09/18/16 01:45:28 PM
#763   Alimera Sciences, In (ALIM) mick 09/04/16 04:10:40 PM
#762   ALIM bullish 1.5 stocktrademan 08/19/16 04:39:38 PM
#761   I put this one on my radar. Seems docoroc2 08/19/16 10:57:33 AM
#760   Anybody knows why this is going down? Any reason? Wesley1961 08/18/16 02:54:47 PM
#759   ALIM bullish 1.74 stocktrademan 08/15/16 12:32:38 PM
#758   ALIM News: Prospectus Filed Pursuant to Rule 424(b)(5) mick 08/14/16 12:35:39 PM
#757   Alimera Sciences, In (ALIM) mick 08/14/16 12:35:27 PM
#756   Market finds this financing positive rancher64 08/12/16 10:53:38 AM
#755   Practically No dilution-expecting Record Revenue & path to rancher64 08/11/16 10:58:56 AM
#754   ALIM News: Current Report Filing (8-k) 09:40 AM mick 08/11/16 10:52:43 AM
#753   Alimera Sciences, In (ALIM) mick 08/11/16 10:52:35 AM
#752   I am going to stay positive. Raising money UserBob 08/11/16 09:44:47 AM
#751   I hope you guys are right bc I Wesley1961 08/11/16 09:22:53 AM
#750   Still pretty sure this is a good stock . bullrunner7 08/11/16 01:42:37 AM
#749   ALIM's EU Potential rancher64 08/11/16 01:42:15 AM
#748   Panic Sell AH rancher64 08/10/16 07:45:48 PM
#747   The same will happen to SPHS. Wesley1961 08/10/16 06:50:01 PM
#746   Hmmm. where are those specialists who have been Wesley1961 08/10/16 06:49:14 PM
#745   Dilution UserBob 08/10/16 05:28:43 PM
#744   Ugh! UserBob 08/10/16 05:18:34 PM
#743   ALIM offering Wildbilly 08/10/16 04:15:31 PM
#742   someone has placed and order to buy 40000 guchu 08/09/16 12:26:12 PM
#741   Alimera Sciences announces clinical presentations and sponsored Symposia guchu 08/09/16 09:30:09 AM
#740   Strong Support at $1.7x. rancher64 08/09/16 01:13:18 AM
#739   Diabetic Macular Edema Patients Gain Or Maintain Vision guchu 08/08/16 11:56:22 PM
#738   Alimera Sciences, Inc.’s Return on Investment stands at guchu 08/07/16 09:49:46 PM
#737   2017 Valuation rancher64 08/07/16 01:38:09 PM
#736   Timber CarlCarlMcB 08/06/16 10:26:09 PM
#735   All Blue Sky .... rancher64 08/05/16 10:47:34 PM
#734   State Street Corp increased its position in Alimera guchu 08/05/16 06:02:44 PM
#733   Alimera Sciences’ (ALIM) “Market Perform” Rating Reaffirmed at guchu 08/05/16 06:01:41 PM
#732   Time to load...accumulation over. rancher64 08/05/16 02:51:27 PM
#731   total number of share shorted 1,259,500 and guchu 08/05/16 02:46:57 PM
#730   What Analysts Say about ALIM. The Company guchu 08/05/16 12:16:49 PM
#729   Increased Volatility Sighted on Shares of Alimera Sciences, guchu 08/05/16 12:04:35 PM
#728   two analyst upgraded to hold and one buy. guchu 08/05/16 09:18:16 AM